RhumbLine Advisers’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-150,169
| Closed | -$3.55M | – | 4278 |
|
|
2023
Q4 | $3.55M | Buy |
150,169
+20,665
| +16% | +$488K | ﹤0.01% | 1612 |
|
|
2023
Q3 | $1.93M | Buy |
129,504
+3,478
| +3% | +$51.9K | ﹤0.01% | 1878 |
|
|
2023
Q2 | $1.38M | Buy |
+126,026
| New | +$1.38M | ﹤0.01% | 2125 |
|
|
2022
Q2 | – | Sell |
-101,595
| Closed | -$316K | – | 3279 |
|
|
2022
Q1 | $316K | Sell |
101,595
-4,107
| -4% | -$12.8K | ﹤0.01% | 2628 |
|
|
2021
Q4 | $357K | Sell |
105,702
-485
| -0.5% | -$1.64K | ﹤0.01% | 2647 |
|
|
2021
Q3 | $388K | Buy |
106,187
+2,086
| +2% | +$7.62K | ﹤0.01% | 2667 |
|
|
2021
Q2 | $454K | Sell |
104,101
-12,360
| -11% | -$53.9K | ﹤0.01% | 2605 |
|
|
2021
Q1 | $529K | Sell |
116,461
-5,480
| -4% | -$24.9K | ﹤0.01% | 2471 |
|
|
2020
Q4 | $700K | Buy |
121,941
+14,581
| +14% | +$83.7K | ﹤0.01% | 2298 |
|
|
2020
Q3 | $777K | Sell |
107,360
-14,165
| -12% | -$103K | ﹤0.01% | 2089 |
|
|
2020
Q2 | $424K | Buy |
121,525
+36,638
| +43% | +$128K | ﹤0.01% | 2422 |
|
|
2020
Q1 | $126K | Hold |
84,887
| – | – | ﹤0.01% | 2730 |
|
|
2019
Q4 | $166K | Sell |
84,887
-118
| -0.1% | -$231 | ﹤0.01% | 2792 |
|
|
2019
Q3 | $435K | Sell |
85,005
-575
| -0.7% | -$2.94K | ﹤0.01% | 2397 |
|
|
2019
Q2 | $613K | Buy |
85,580
+7,737
| +10% | +$55.4K | ﹤0.01% | 2272 |
|
|
2019
Q1 | $1.03M | Sell |
77,843
-103
| -0.1% | -$1.37K | ﹤0.01% | 2020 |
|
|
2018
Q4 | $613K | Buy |
77,946
+25,057
| +47% | +$197K | ﹤0.01% | 2205 |
|
|
2018
Q3 | $586K | Sell |
52,889
-2,372
| -4% | -$26.3K | ﹤0.01% | 2218 |
|
|
2018
Q2 | $742K | Buy |
+55,261
| New | +$742K | ﹤0.01% | 2142 |
|